DE69433685D1 - Unterdrückung von inhibitoren - Google Patents

Unterdrückung von inhibitoren

Info

Publication number
DE69433685D1
DE69433685D1 DE69433685T DE69433685T DE69433685D1 DE 69433685 D1 DE69433685 D1 DE 69433685D1 DE 69433685 T DE69433685 T DE 69433685T DE 69433685 T DE69433685 T DE 69433685T DE 69433685 D1 DE69433685 D1 DE 69433685D1
Authority
DE
Germany
Prior art keywords
ipnme
methods
compounds
malignant tumour
suppression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69433685T
Other languages
English (en)
Other versions
DE69433685T2 (de
Inventor
Nils Bruenner
John Romer
Vincent Ellis
Charles Pyke
Jan Grondahl-Hansen
Helle Pedersen
Hoi Hansen
Keld Dano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancerforskningsfondet af 1989
Original Assignee
Cancerforskningsfondet af 1989
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancerforskningsfondet af 1989 filed Critical Cancerforskningsfondet af 1989
Application granted granted Critical
Publication of DE69433685D1 publication Critical patent/DE69433685D1/de
Publication of DE69433685T2 publication Critical patent/DE69433685T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
DE69433685T 1993-07-16 1994-07-18 Unterdrückung von inhibitoren Expired - Lifetime DE69433685T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK85193 1993-07-16
DK93851A DK85193D0 (da) 1993-07-16 1993-07-16 Suppression of inhibitors
PCT/DK1994/000288 WO1995002413A1 (en) 1993-07-16 1994-07-18 Suppression of inhibitors

Publications (2)

Publication Number Publication Date
DE69433685D1 true DE69433685D1 (de) 2004-05-13
DE69433685T2 DE69433685T2 (de) 2005-03-03

Family

ID=8098263

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433685T Expired - Lifetime DE69433685T2 (de) 1993-07-16 1994-07-18 Unterdrückung von inhibitoren

Country Status (9)

Country Link
US (4) US6224865B1 (de)
EP (1) EP0712312B1 (de)
JP (1) JPH10500097A (de)
AT (1) ATE263569T1 (de)
AU (1) AU7183394A (de)
DE (1) DE69433685T2 (de)
DK (1) DK85193D0 (de)
ES (1) ES2217268T3 (de)
WO (1) WO1995002413A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK85193D0 (da) * 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
US6811995B1 (en) * 1996-04-26 2004-11-02 Children's Medical Center Corporation Non-invasive enzyme screen for cancer
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
US6750201B1 (en) 1997-10-17 2004-06-15 The Trustees Of The University Of Pennsylvania Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
EP1030679A4 (de) * 1997-10-17 2003-03-05 Univ Pennsylvania Zusammenstellungen und Verfahren zur verbesserten Internalisierung und Abbau von Urokinase-Typ Plasminogen Aktivator
US6841153B1 (en) 1998-10-02 2005-01-11 University Of Florida Prevention of adhesions
WO2000050057A1 (en) * 1999-02-22 2000-08-31 Bernstein Eric F Compositions and methods for prevention of photoaging
US6986881B1 (en) * 1999-06-04 2006-01-17 Dana-Farber Cancer Institute, Inc. Identification of compounds that modify transcriptional responses to hypoxia
EP2302385B1 (de) * 2002-02-13 2014-12-03 Sekisui Diagnostics, LLC Verfahren zur Auswahl der Behandlungsabläufe und Vorhersage der Ergebnisse bei Krebspatienten
WO2005106475A2 (en) * 2004-04-16 2005-11-10 Wyeth Novel method for determination of plasminogen activator inhibitor
EP1814899A4 (de) * 2004-11-18 2008-09-03 Univ Illinois Multicistronische sirna-konstrukte zur tumorhemmung
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
US20070021365A1 (en) * 2005-06-21 2007-01-25 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto
JP4417424B2 (ja) * 2006-06-01 2010-02-17 国立がんセンター総長 発がん抑制剤
US7981415B2 (en) * 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
US7771720B2 (en) * 2007-09-07 2010-08-10 Cisthera, Inc. Humanized PAI-1 antibodies
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
MX2016001851A (es) * 2013-08-13 2016-05-16 Sanofi Sa Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos.
US9689874B2 (en) 2015-04-10 2017-06-27 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK319685A (da) * 1985-07-12 1987-01-13 Fonden Til Fremme Af Eksperime Monoklonale antistoffer, fremgangsmaade til frembringelse af antistofferne, hybridomaceller, der producerer antistofferne, og anvendelse af antistofferne
US4906457A (en) * 1988-09-06 1990-03-06 Washington State University Research Foundation, Inc. Compositions and methods for reducing the risk of sunlight and ultraviolet induced skin cancer
CA2452130A1 (en) * 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
US5744442A (en) * 1992-08-26 1998-04-28 Bristol Meyers Squibb Company Regulation of cellular invasiveness
DK85193D0 (da) * 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
US5800814A (en) 1994-04-22 1998-09-01 Oklahoma Medical Research Foundation Method for inhibition of breast tumor growth
GB9410387D0 (en) 1994-05-24 1994-07-13 Xenova Ltd Pharmaceutical compounds
BR9612619A (pt) 1996-05-15 1999-07-20 Altarex Inc Método e composição para reconformar antígenos multiepitópicos para iniciar uma resposta imunológica
EP1381631B1 (de) * 2001-04-24 2010-10-13 Bayer Corporation Menschliche antikörper gegen timp-1
JP2007530603A (ja) * 2004-03-30 2007-11-01 デン コンゲリク ベテリネル−オク ランドボホイスコレ プロテアーゼ阻害物質の遮断又は検出による癌治療及び癌治療効能予測の改善

Also Published As

Publication number Publication date
WO1995002413A1 (en) 1995-01-26
JPH10500097A (ja) 1998-01-06
ATE263569T1 (de) 2004-04-15
US20010034327A1 (en) 2001-10-25
US20080166354A1 (en) 2008-07-10
DK85193D0 (da) 1993-07-16
US6224865B1 (en) 2001-05-01
EP0712312B1 (de) 2004-04-07
US20030096755A1 (en) 2003-05-22
AU7183394A (en) 1995-02-13
EP0712312A1 (de) 1996-05-22
DE69433685T2 (de) 2005-03-03
ES2217268T3 (es) 2004-11-01

Similar Documents

Publication Publication Date Title
ATE263569T1 (de) Unterdrückung von inhibitoren
GR3033103T3 (en) Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
Howes et al. Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators
ATE369871T1 (de) Verfahren zur behandlung von hautkrebs mittels zusammensetzungen, die einen endothelinrezeptor-b-hemmer enthalten
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
CY1107484T1 (el) Παραγωγα γκελνταναμυκινης χρησιμοποιουμενα για τη θεραπεια καρκινου
NO962568L (no) Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom
MXPA05006359A (es) Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos.
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
WO2004010937A3 (en) Method of treating cancer
WO2000051623A3 (en) Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
MY110104A (en) Saccharin derivative proteolytic enzyme inhibitors
ATE385807T1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
NZ331484A (en) Serine protease inhibitors having an alkynylamino side chain for use in treatment of thrombin related diseases
ATE277943T1 (de) Trypsininhibitoren
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
DE69912432D1 (de) Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
TR199802638T2 (xx) Kanser tedavisinde naaladase inhibit�rleri kullan�m�.
AU1565599A (en) A method for the prevention and treatment of stunned myocardium
HUP9801022A2 (hu) Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására
WO2002064172A3 (en) Fhit gene therapy prevents tumor development in fhit-deficient mice
HUP0103660A2 (hu) Mikróbaeredetű hialuronsavbontó enzimet tartalmazó gyógyászati készítmény
WO2002074756A3 (de) Urokinase-inhibitoren
ATE250030T1 (de) Peptidverbindungen mit mmp- und tnf-hemmender wirkung
NZ531109A (en) New mandelic acid derivatives and their use as thrombin inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition